Compare Pfizer Inc (PFE) vs Unum Group Common Stock (UNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Unum Group Common Stock — how do they compare? Pfizer Inc trades at $29.49 (market cap $166.49B), while Unum Group Common Stock trades at $91.42 (market cap $14.48B). The key difference: Pfizer Inc is far larger — about 11.5× Unum Group Common Stock's market cap, and Pfizer Inc pays the higher dividend (5.89%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Unum Group Common Stock for 0 Days on average.
| PFE | UNM | |
|---|---|---|
Market Cap | $166.49B | $14.48B |
Volume | 39,330,520 | 2,214,044 |
Sector | Health | Financials |
52-Week High | $29.21 | $96.57 |
52-Week Low | $23.67 | $70.66 |
Typical Hold Time | 158 Days | 0 Days |
Enterprise Value | $217.98B | $18.04B |
Dividend Yield | 5.89% | 2.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.37, down slightly by 0.11% on the day, with a bullish technical signal from moving averages. The company maintains strong profitability with a 73.18% gross margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on obesity and oncology pipeline developments, positioning for a catalyst-rich 2026.
Pfizer presents a mixed outlook with stable revenue around $63B but declining net income projections for 2026. The stock trades near analyst consensus target of $29.17, offering modest upside potential. Key risks include patent cliffs and competitive pressures, while the dividend yield and pipeline progress provide defensive appeal for income-focused investors.
Unum Group (UNM) trades at $92.05, down 0.5% with neutral technical signals. The stock shows mixed earnings performance with Q1 2026 beating estimates but Q4 2025 and Q2 2026 missing expectations. Analyst consensus is positive with 50% buy ratings and a $101 price target representing 9.7% upside. The company maintains stable profitability with 5.31% net margin and recently announced a $1 billion share repurchase program to enhance shareholder returns.
UNM presents a balanced investment case with strong institutional support and shareholder-friendly capital returns, though earnings consistency remains a concern. The stock trades at reasonable valuations (P/E 21.36, P/S 1.15) with potential upside to analyst targets. Key risks include premium growth sustainability and claims experience volatility in the insurance operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Unum Group Common Stock
Unum Group provides workplace benefits, including disability, life, accident, critical illness, dental, and vision insurance, along with leave management services. It serves employers through its Unum US, Unum International, and Colonial Life segments, distributing coverage via brokers and independent agents.
Read more on UNM →
